![Transparency Market Researchが調査・発行した産業分析レポートです。呼吸器疾患治療の世界市場2019-2027：疾患別（喘息、慢性閉塞性肺疾患[COPD]、肺癌、呼吸器感染症、アレルギー性鼻炎、嚢胞性線維症[CF]、その他）、薬物クラス別、投与経路別、流通経路別 / Respiratory Disorders Treatment Market (Disease: Asthma, Chronic Obstructive Pulmonary Disease [COPD], Lung Cancer, Respiratory Tract Infection, Allergic Rhinitis, Cystic Fibrosis [CF], and Others; Drug Class: Bronchodilators, Corticosteroids, Combination Drugs, Antibiotics, Target Therapy, Immunotherapy, CFTR, and Others; Route of Administration: Oral, Nasal, and Injectable; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027 / TMR2006019資料のイメージです。](https://www.marketresearch.co.jp/images-folder2/99x123xreport-contents-80.gif.pagespeed.ic.cYgo-ZH9PJ.jpg) | • レポートコード：TMR2006019 • 出版社/出版日：Transparency Market Research / 2020年3月 • レポート形態：英文、PDF、182ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、呼吸器疾患治療の世界市場について、序論、仮定・調査手法、エグゼクティブサマリー、市場動向、キーインサイト、疾患別（喘息、慢性閉塞性肺疾患[COPD]、肺癌、呼吸器感染症、アレルギー性鼻炎、嚢胞性線維症[CF]、その他）分析、薬物クラス別分析、投与経路別分析、流通経路別分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東アフリカ）分析、競争状況などを総合的に調査・分析して掲載しております。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場動向 ・キーインサイト ・呼吸器疾患治療の世界市場規模：疾患別（喘息、慢性閉塞性肺疾患[COPD]、肺癌、呼吸器感染症、アレルギー性鼻炎、嚢胞性線維症[CF]、その他） ・呼吸器疾患治療の世界市場規模：薬物クラス別 ・呼吸器疾患治療の世界市場規模：投与経路別 ・呼吸器疾患治療の世界市場規模：流通経路別 ・呼吸器疾患治療の世界市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東アフリカ） ・競争状況 |
Respiratory Disorders Treatment Market – Scope of the Report
TMR’s report on the global respiratory disorders treatment market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period from 2019 to 2027. The report provides revenue of the global respiratory disorders treatment market for the period from 2017 to 2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global respiratory disorders treatment market during the forecast period.
The report has been prepared after primary and secondary researches. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global respiratory disorders treatment market.
Secondary research also includes Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global respiratory disorders treatment market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on changing competitive dynamics in the global respiratory disorders treatment market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global respiratory disorders treatment market.
The report delves into the competitive landscape of the global respiratory disorders treatment market. Key players operating in the global respiratory disorders treatment market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global respiratory disorders treatment market that have been profiled in this report.
Key Questions Answered in Respiratory Disorders Treatment Market Report
What is the scope of growth of combination drugs in the global respiratory disorders treatment market?
What will be the Y-o-Y growth of the global respiratory disorders treatment market between 2019 and 2027?
What is the influence of changing trends in target therapies on the global respiratory disorders treatment market?
Will North America continue to be the most profitable regional market for respiratory disorders treatment providers?
Which factors are anticipated to hamper the growth of the global respiratory disorders treatment market during the forecast period?
Which are the leading companies in the global respiratory disorders treatment market?
Research Methodology
A unique research methodology has been utilized by TMR to conduct comprehensive research on the growth of the global respiratory disorders treatment market. This research methodology is a combination of primary and secondary researches, which helps analysts to warrant the accuracy and reliability of the drawn conclusions.
Secondary methods referred to by analysts during the production of the global respiratory disorders treatment market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the respiratory disorders treatment market.
These primary and secondary methods have provided exclusive information during interviews, which serves as a validation from the respiratory disorders treatment market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global respiratory disorders treatment market with accuracy. The study also uses the top-down approach to assess the revenue for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future projection of the global respiratory disorders treatment market more reliably and accurately.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Respiratory Disorders Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Route of Administration Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Respiratory Disorders Treatment Market Analysis and Forecast, 2017–2027
4.4.1. Market Revenue Projections (US$ Bn)
4.5. Porter’s Five Force Analysis
5. Key Insights
5.1. Health Care Industry Overview
5.2. Health Care Industry Overview
5.3. Pipeline Analysis (asthma, lung cancer, COPD)
5.4. Disease Prevalence Rate in Key Countries
5.5. Disease Management
5.6. Key Market Events
5.7. Regulatory Scenario
5.8. Reimbursement Scenario
5.9. Technological Advancements
6. Global Respiratory Disorders Treatment Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.1.1. Key Findings / Developments
6.2. Global Respiratory Disorders Treatment Market Value Forecast, by Drug Class, 2017–2027
6.2.1. Bronchodilators
6.2.2. Corticosteroids
6.2.3. Combination Drugs
6.2.4. Antibiotics
6.2.5. Target Therapy
6.2.6. Immunotherapy
6.2.7. CFTR
6.3. Others Global Respiratory Disorders Treatment Market Attractiveness Analysis, by Drug Class
7. Global Respiratory Disorders Treatment Market Analysis and Forecast, by Disease
7.1. Introduction & Definition
7.1.1. Key Findings / Developments
7.2. Global Respiratory Disorders Treatment Market Value Forecast, by Disease, 2017–2027
7.2.1. Asthma
7.2.2. Chronic Obstructive Pulmonary Disease (COPD)
7.2.3. Lung Cancer
7.2.4. Respiratory Tract Infection
7.2.5. Allergic Rhinitis
7.2.6. Cystic Fibrosis (CF)
7.2.7. Others
7.3. Global Respiratory Disorders Treatment Market Attractiveness Analysis, by Disease
8. Global Respiratory Disorders Treatment Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.1.1. Key Findings / Developments
8.2. Global Respiratory Disorders Treatment Market Value Forecast, by Route of Administration, 2017–2027
8.2.1. Oral
8.2.2. Nasal
8.2.3. Injectable
8.3. Global Respiratory Disorders Treatment Market Attractiveness Analysis, by Route of Administration
9. Global Respiratory Disorders Treatment Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.1.1. Key Findings / Developments
9.2. Global Respiratory Disorders Treatment Market Value Forecast, by Distribution Channel, 2017–2027
9.2.1. Hospital Pharmacies
9.2.2. Retail Pharmacies
9.2.3. Online Pharmacies
9.3. Global Respiratory Disorders Treatment Market Attractiveness Analysis, by Distribution Channel
10. Global Respiratory Disorders Treatment Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Global Respiratory Disorders Treatment Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. North America Respiratory Disorders Treatment Market Attractiveness Analysis, by Region
11. North America Respiratory Disorders Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027
11.2.1. Bronchodilators
11.2.2. Corticosteroids
11.2.3. Combination Drugs
11.2.4. Antibiotics
11.2.5. Target Therapy
11.2.6. Immunotherapy
11.2.7. CFTR
11.3. North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027
11.3.1. Asthma
11.3.2. Chronic Obstructive Pulmonary Disease (COPD)
11.3.3. Lung Cancer
11.3.4. Respiratory Tract Infection
11.3.5. Allergic Rhinitis
11.3.6. Cystic Fibrosis (CF)
11.3.7. Others
11.4. North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027
11.4.1. Oral
11.4.2. Nasal
11.4.3. Injectable
11.5. North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country, 2017–2027
11.6.1. U.S.
11.6.2. Canada
11.7. North America Respiratory Disorders Treatment Market Attractiveness Analysis
11.7.1. By Drug Class
11.7.2. By Disease
11.7.3. By Route of Administration
11.7.4. By Distribution Channel
11.7.5. By Country
12. Europe Respiratory Disorders Treatment Market Analysis and Forecast
12.1. Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027
12.1.1. Bronchodilators
12.1.2. Corticosteroids
12.1.3. Combination Drugs
12.1.4. Antibiotics
12.1.5. Target Therapy
12.1.6. Immunotherapy
12.1.7. CFTR
12.2. Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027
12.2.1. Asthma
12.2.2. Chronic Obstructive Pulmonary Disease (COPD)
12.2.3. Lung Cancer
12.2.4. Respiratory Tract Infection
12.2.5. Allergic Rhinitis
12.2.6. Cystic Fibrosis (CF)
12.2.7. Others
12.3. Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027
12.3.1. Oral
12.3.2. Nasal
12.3.3. Injectable
12.4. Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2027
12.5.1. Germany
12.5.2. U.K.
12.5.3. France
12.5.4. Spain
12.5.5. Italy
12.5.6. Rest of Europe
12.6. Europe Respiratory Disorders Treatment Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Disease
12.6.3. By Route of Administration
12.6.4. By Distribution Channel
12.6.5. By Country/Sub-region
13. Asia Pacific Respiratory Disorders Treatment Market Analysis and Forecast
13.1. Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027
13.1.1. Bronchodilators
13.1.2. Corticosteroids
13.1.3. Combination Drugs
13.1.4. Antibiotics
13.1.5. Target Therapy
13.1.6. Immunotherapy
13.1.7. CFTR
13.2. Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027
13.2.1. Asthma
13.2.2. Chronic Obstructive Pulmonary Disease (COPD)
13.2.3. Lung Cancer
13.2.4. Respiratory Tract Infection
13.2.5. Allergic Rhinitis
13.2.6. Cystic Fibrosis (CF)
13.2.7. Others
13.3. Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027
13.3.1. Oral
13.3.2. Nasal
13.3.3. Injectable
13.4. Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2027
13.5.1. China
13.5.2. Japan
13.5.3. India
13.5.4. Australia & New Zealand
13.5.5. Rest of Asia Pacific
13.6. Asia Pacific Respiratory Disorders Treatment Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Disease
13.6.3. By Route of Administration
13.6.4. By Distribution Channel
13.6.5. By Country/Sub-region
14. Latin America Respiratory Disorders Treatment Market Analysis and Forecast
14.1. Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027
14.1.1. Bronchodilators
14.1.2. Corticosteroids
14.1.3. Combination Drugs
14.1.4. Antibiotics
14.1.5. Target Therapy
14.1.6. Immunotherapy
14.1.7. CFTR
14.2. Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027
14.2.1. Asthma
14.2.2. Chronic Obstructive Pulmonary Disease (COPD)
14.2.3. Lung Cancer
14.2.4. Respiratory Tract Infection
14.2.5. Allergic Rhinitis
14.2.6. Cystic Fibrosis (CF)
14.2.7. Others
14.3. Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027
14.3.1. Oral
14.3.2. Nasal
14.3.3. Injectable
14.4. Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2027
14.5.1. Brazil
14.5.2. Mexico
14.5.3. Rest of Latin America Latin America
14.6. Latin America Respiratory Disorders Treatment Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Disease
14.6.3. By Route of Administration
14.6.4. By Distribution Channel
14.6.5. By Country/Sub-region
15. Middle East & Africa Respiratory Disorders Treatment Market Analysis and Forecast
15.1. Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027
15.1.1. Bronchodilators
15.1.2. Corticosteroids
15.1.3. Combination Drugs
15.1.4. Antibiotics
15.1.5. Target Therapy
15.1.6. Immunotherapy
15.1.7. CFTR
15.2. Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027
15.2.1. Asthma
15.2.2. Chronic Obstructive Pulmonary Disease (COPD)
15.2.3. Lung Cancer
15.2.4. Respiratory Tract Infection
15.2.5. Allergic Rhinitis
15.2.6. Cystic Fibrosis (CF)
15.2.7. Others
15.3. Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027
15.3.1. Oral
15.3.2. Nasal
15.3.3. Injectable
15.4. Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027
15.4.1. Hospital Pharmacies
15.4.2. Retail Pharmacies
15.4.3. Online Pharmacies
15.5. Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2027
15.5.1. GCC Countries
15.5.2. South Africa
15.5.3. Rest of Middle East & Africa
15.6. Middle East & Africa Respiratory Disorders Treatment Market Attractiveness Analysis
15.6.1. By Drug Class
15.6.2. By Disease
15.6.3. By Route of Administration
15.6.4. By Distribution Channel
15.6.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (by Tier and Size of companies)
16.2. Market Share / Position Analysis, by Company, 2018
16.3. Competitive Business Strategies
16.4. Company Profiles
16.4.1. GlaxoSmithKline plc
16.4.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.1.2. Growth Strategies
16.4.1.3. SWOT Analysis
16.4.2. Merck & Co., Inc.
16.4.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.2.2. Growth Strategies
16.4.2.3. SWOT Analysis
16.4.3. AstraZeneca
16.4.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.3.2. Growth Strategies
16.4.3.3. SWOT Analysis
16.4.4. Boehringer Ingelheim International GmbH
16.4.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.4.2. Growth Strategies
16.4.4.3. SWOT Analysis
16.4.5. Novartis AG
16.4.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.5.2. Growth Strategies
16.4.5.3. SWOT Analysis
16.4.6. F. Hoffmann-La Roche Ltd.
16.4.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.6.2. Growth Strategies
16.4.6.3. SWOT Analysis
16.4.7. Teva Pharmaceutical Industries Ltd.
16.4.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.7.2. Growth Strategies
16.4.7.3. SWOT Analysis
16.4.8. Sanofi
16.4.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.8.2. Growth Strategies
16.4.8.3. SWOT Analysis
16.4.9. Cipla, Inc.
16.4.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.9.2. Growth Strategies
16.4.9.3. SWOT Analysis
16.4.10. Sun Pharmaceutical Industries Ltd.
16.4.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.10.2. Growth Strategies
16.4.10.3. SWOT Analysis
16.4.11. Mylan N.V.
16.4.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.11.2. Growth Strategies
16.4.11.3. SWOT Analysis
16.4.12. Takeda Pharmaceutical Company Limited
16.4.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.12.2. Growth Strategies
16.4.12.3. SWOT Analysis
16.4.13. CHIESI Farmaceutici S.p.A.
16.4.13.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.13.2. Growth Strategies
16.4.13.3. SWOT Analysis
16.4.14. Orion Corporation
16.4.14.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.14.2. Growth Strategies
16.4.14.3. SWOT Analysis
16.4.15. Vertex Pharmaceutical
16.4.15.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.15.2. Growth Strategies
16.4.15.3. SWOT Analysis
List of TablesTable 01: Global Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027
Table 02: Global Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027
Table 03: Global Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027
Table 04: Global Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027
Table 05: Global Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Region, 2017–2027
Table 06: North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country, 2017–2027
Table 07: North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027
Table 08: North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027
Table 09: North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027
Table 10: North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027
Table 11: Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2027
Table 12: Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027
Table 13: Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027
Table 14: Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027
Table 15: Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027
Table 16: Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2027
Table 17: Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027
Table 18: Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027
Table 19: Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027
Table 20: Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027
Table 21: Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2027
Table 22: Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027
Table 23: Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027
Table 24: Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027
Table 25: Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027
Table 26: Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2027
Table 27: Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027
Table 28: Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027
Table 29: Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027
Table 30: Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027